


Prevent Breast Cancer Trading Company Limited (formerly known as Genesis Breast Cancer Prevention Appeal Trading Company Limited)

Registered number: 07030621

Directors' report and financial statements

For the year ended 31 March 2016



PREVENT BREAST CANCER TRADING COMPANY LIMITED

COMPANY INFORMATION

Directors	C Levine L Barr
Company secretary	J M Glass
Registered number	07030621
Registered office	The Nightingale Centre Wythenshawe Hospital Southmoor Road Manchester M23 9LT
Independent auditor	Mazars LLP Chartered Accountants & Statutory Auditor The Lexicon Mount Street Manchester M2 5NT
Bankers	Royal Bank of Scotland PLC Manchester M60 2BE
Solicitors	Gunnercooke LLP Riverside New Bailey Street Manchester M3 5FS

PREVENT BREAST CANCER TRADING COMPANY LIMITED

CONTENTS

	Page
Directors' Report	1 - 2
Independent Auditor's Report	3 - 4
Statement of Comprehensive Income	5
Balance Sheet	6
Statement of Changes in Equity	7 - 8
Notes to the Financial Statements	9 - 12

PREVENT BREAST CANCER TRADING COMPANY LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 31 MARCH 2016

The directors present their report and the financial statements for the year ended 31 March 2016.

Directors' responsibilities statement

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under Company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the Company's financial statements and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Results and dividends

The profit for the year, after taxation, amounted to £16,008 (2015 - £17,202).

The directors recommend a distribution payment to the parent Charitable Company of £16,008.

Directors

The directors who served during the year were:

C Levine
L Barr

Future developments

In 2017 the charity will continue to develop its trading activities by investing in branded merchandise, which reflects the new name of the charity and incorporates the revised colour palette. By doing so we hope to increase sales of our merchandise, which will in turn raise awareness of our cause. We will also be looking at ways to improve our visibility online and by doing so our aim is to increase sales of merchandise, including Christmas cards through our website.

PREVENT BREAST CANCER TRADING COMPANY LIMITED

**DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2016**

Disclosure of information to auditor

Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:

- so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and
- the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Post balance sheet events

On 13 May 2016, the Company changed its name from Genesis Breast Cancer Prevention Appeal Trading Company Limited to Prevent Breast Cancer Trading Company Limited.

This report was approved by the board on 6 December 2016 and signed on its behalf.



L Barr
Director

PREVENT BREAST CANCER TRADING COMPANY LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF PREVENT BREAST CANCER TRADING COMPANY LIMITED

We have audited the financial statements of Prevent Breast Cancer Trading Company Limited for the year ended 31 March 2016 which comprise the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard FRS 102 "The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland".

Respective responsibilities of directors and auditor

As explained more fully in the Directors' Responsibilities Statement set out on page 1, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors. This report is made solely to the Company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body for our audit work, for this report, or for the opinions we have formed.

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the Financial Reporting Council's website at www.frc.org.uk/auditscopeukprivate.

Opinion on the financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the Company's affairs as at 31 March 2016 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on the other matter prescribed by the Companies Act 2006

In our opinion the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.


PREVENT BREAST CANCER TRADING COMPANY LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF PREVENT BREAST CANCER TRADING COMPANY LIMITED

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.



Janine Fox (Senior Statutory Auditor)

for and on behalf of Mazars LLP

Chartered Accountants and Statutory Auditor

The Lexicon
Mount Street
Manchester
M2 5NT

Date: 16 December 2016

PREVENT BREAST CANCER TRADING COMPANY LIMITED

**STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2016**

	Note	2016 £	2015 £
Turnover	4	46,603	40,722
Cost of sales		(30,595)	(23,520)
Gross profit		<u>16,008</u>	<u>17,202</u>
Profit for the year		<u><u>16,008</u></u>	<u><u>17,202</u></u>

There was no other comprehensive income for 2016 (2015: £NIL).

The notes on pages 9 to 12 form part of these financial statements.

PREVENT BREAST CANCER TRADING COMPANY LIMITED
REGISTERED NUMBER: 07030621


BALANCE SHEET
AS AT 31 MARCH 2016

	Note	£	2016 £	£	2015 £
Current assets					
Stocks	10	7,279		9,690	
		<u>7,279</u>		<u>9,690</u>	
Creditors: amounts falling due within one year	11	(7,278)		(9,689)	
		<u></u>		<u></u>	
Net current assets			1		1
Total assets less current liabilities			<u>1</u>		<u>1</u>
Net assets			<u><u>1</u></u>		<u><u>1</u></u>
Capital and reserves					
Called up share capital	13		1		1
			<u>1</u>		<u>1</u>

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on

8/12/2016



L Barr
Director

The notes on pages 9 to 12 form part of these financial statements.

PREVENT BREAST CANCER TRADING COMPANY LIMITED

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2016**

	Called up share capital	Profit and loss account	Total equity
	£	£	£
At 1 April 2015	1	-	1
Comprehensive income for the year			
Profit for the year	-	16,008	16,008
Other comprehensive income for the year	-	-	-
Total comprehensive income for the year	-	16,008	16,008
Distribution to parent charity	-	(16,008)	(16,008)
Total transactions with owners	-	(16,008)	(16,008)
At 31 March 2016	<u>1</u>	<u>-</u>	<u>1</u>

PREVENT BREAST CANCER TRADING COMPANY LIMITED

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2015**

	Called up share capital	Profit and loss account	Total equity
	£	£	£
At 1 April 2014	1	-	1
Comprehensive income for the year			
Profit for the year	-	17,202	17,202
Other comprehensive income for the year	-	-	-
Total comprehensive income for the year	-	17,202	17,202
Distribution to parent charity	-	(17,202)	(17,202)
Total transactions with owners	-	(17,202)	(17,202)
At 31 March 2015	1	-	1

The notes on pages 9 to 12 form part of these financial statements.

PREVENT BREAST CANCER TRADING COMPANY LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2016

1. General information

Prevent Breast Cancer Trading Limited ("the Company") is a private limited company incorporated in England. The address of its registered office and principal place of business is:

The Nightingale Centre
Wythenshawe Hospital
Southmoor Road
Manchester
M23 9LT

The principal activity of the company is that of selling general retail merchandise.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

Information on the impact of first-time adoption of FRS 102 is given in note 15.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

2.2 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:

- the Company has transferred the significant risks and rewards of ownership to the buyer;
- the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2016**

2. Accounting policies (continued)

2.3 Stocks

Stocks are stated at the lower of cost and net realisable value

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

2.4 Financial instruments

The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Profit and Loss Account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

2.5 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

3. Judgements in applying accounting policies and key sources of estimation uncertainty

In applying the Company's accounting policies, the directors are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The directors' judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable. Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

4. Turnover

All turnover arose within the United Kingdom.

5. Operating profit

During the year, no director received any emoluments (2015 - £NIL).

PREVENT BREAST CANCER TRADING COMPANY LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2016

6. Auditor's remuneration

Audit and non-audit fees are borne by the ultimate parent company.

7. Employees

The Company has no employees other than the directors, who did not receive any remuneration (2015 - £NIL).

8. Taxation

There were no factors that affected the tax charge for the year which has been calculated on the profits on ordinary activities before tax at the standard rate of corporation tax in the UK of 20% (2015 - 20%).

The profit in both the current and prior year has been recognised as a distribution in full to the ultimate parent which results in no tax charge in either year.

9. Distributions

	2016 £	2015 £
Distribution to parent charity	16,008	17,202
	<u>16,008</u>	<u>17,202</u>

10. Stocks

	2016 £	2015 £
Goods for resale	7,279	9,690
	<u>7,279</u>	<u>9,690</u>

Stock recognised in cost of sales during the year as an expense was £30,594 (2015 - £23,520).

An impairment loss on stock of £3,997 was recognised within cost of sales (2015 - £nil).

11. Creditors: Amounts falling due within one year

	2016 £	2015 £
Amounts owed to group undertakings	7,278	9,689
	<u>7,278</u>	<u>9,689</u>

PREVENT BREAST CANCER TRADING COMPANY LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2016**

12. Financial instruments

	2016 £	2015 £
Financial liabilities		
Financial liabilities measured at amortised cost	(7,278)	(9,689)
	<u>(7,278)</u>	<u>(9,689)</u>

Financial liabilities measured at amortised cost comprise amounts owed to group undertakings.

13. Share capital

	2016 £	2015 £
Shares classified as equity		
Allotted, called up and fully paid		
1 Ordinary share of £1	<u>1</u>	<u>1</u>

14. Controlling party

The ultimate parent and controlling party is the Prevent Breast Cancer Limited.

The ultimate parent prepares consolidated financial statements which are available from the registered office.

15. First time adoption of FRS 102

The policies applied under the entity's previous accounting framework are not materially different to FRS 102 and have not impacted on equity or profit or loss.